Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 P27 (Negative Regulatory Factor or Nef) Overview 6 Therapeutics Development 7 P27 (Negative Regulatory Factor or Nef) - Products under Development by Stage of Development 7 P27 (Negative Regulatory Factor or Nef) - Products under Development by Therapy Area 8 P27 (Negative Regulatory Factor or Nef) - Products under Development by Indication 9 P27 (Negative Regulatory Factor or Nef) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 P27 (Negative Regulatory Factor or Nef) - Products under Development by Companies 12 P27 (Negative Regulatory Factor or Nef) - Products under Development by Universities/Institutes 14 P27 (Negative Regulatory Factor or Nef) - Therapeutics Assessment 16 Assessment by Monotherapy/Combination Products 16 Assessment by Mechanism of Action 17 Assessment by Route of Administration 18 Assessment by Molecule Type 20 P27 (Negative Regulatory Factor or Nef) - Drug Profiles 22 HIV vaccine - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 HIV vaccine - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 HIV vaccine 1 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 HIV-1 vaccine 1 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 HIV-1 vaccine 5 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 Monoclonal Antibody Conjugate to Inhibit Gag, Nef, Pol for HIV - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 MVATG-17401 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Small Molecules to Inhibit Nef for HIV-1 Infections - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Tatbeclin-1 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 P27 (Negative Regulatory Factor or Nef) - Dormant Projects 31 P27 (Negative Regulatory Factor or Nef) - Featured News & Press Releases 33 Jan 02, 2015: HIV vaccines should avoid viral target cells, primate model study suggests 33 Appendix 34 Methodology 34 Coverage 34 Secondary Research 34 Primary Research 34 Expert Panel Validation 34 Contact Us 34 Disclaimer 35

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis on P27 (Negative Regulatory Factor or Nef) targeted pipeline therapeutics. The report provides comprehensive information on the P27 (Negative Regulatory Factor or Nef) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in P27 (Negative Regulatory Factor or Nef) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for P27 (Negative Regulatory Factor or Nef) - The report reviews P27 (Negative Regulatory Factor or Nef) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in P27 (Negative Regulatory Factor or Nef) targeted therapeutics and enlists all their major and minor projects - The report assesses P27 (Negative Regulatory Factor or Nef) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to P27 (Negative Regulatory Factor or Nef) targeted therapeutics Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for P27 (Negative Regulatory Factor or Nef) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding P27 (Negative Regulatory Factor or Nef) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeTable of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 P27 (Negative Regulatory Factor or Nef) Overview 6 Therapeutics Development 7 P27 (Negative Regulatory Factor or Nef) - Products under Development by Stage of Development 7 P27 (Negative Regulatory Factor or Nef) - Products under Development by Therapy Area 8 P27 (Negative Regulatory Factor or Nef) - Products under Development by Indication 9 P27 (Negative Regulatory Factor or Nef) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 P27 (Negative Regulatory Factor or Nef) - Products under Development by Companies 12 P27 (Negative Regulatory Factor or Nef) - Products under Development by Universities/Institutes 14 P27 (Negative Regulatory Factor or Nef) - Therapeutics Assessment 16 Assessment by Monotherapy/Combination Products 16 Assessment by Mechanism of Action 17 Assessment by Route of Administration 18 Assessment by Molecule Type 20 P27 (Negative Regulatory Factor or Nef) - Drug Profiles 22 HIV vaccine - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 HIV vaccine - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 HIV vaccine 1 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 HIV-1 vaccine 1 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 HIV-1 vaccine 5 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 Monoclonal Antibody Conjugate to Inhibit Gag, Nef, Pol for HIV - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 MVATG-17401 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Small Molecules to Inhibit Nef for HIV-1 Infections - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Tatbeclin-1 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 P27 (Negative Regulatory Factor or Nef) - Dormant Projects 31 P27 (Negative Regulatory Factor or Nef) - Featured News & Press Releases 33 Jan 02, 2015: HIV vaccines should avoid viral target cells, primate model study suggests 33 Appendix 34 Methodology 34 Coverage 34 Secondary Research 34 Primary Research 34 Expert Panel Validation 34 Contact Us 34 Disclaimer 35